Email:
info@genesbio.com
HANGZHOU GENESEA BIOTECHNOLOGY CO., LTD.
News classification
Detection classification
News Detail

The company's circulating tumor cell CTC product development has made progress

Issuing time:2018-08-23 11:15

Circulating tumor cells (CTC) refer to tumor cells that enter the human peripheral blood. Malignant tumors are transferred to other organs of the body through the blood, which is the main cause of death of tumor patients. CTC is the seed cells of metastatic tumors. The process of tumor metastasis is that the tumor cells first invade into the surrounding tissue of the primary tumor, enter the blood to form circulating tumor cells CTC, and transport to the distant tissue, and then ooze to form metastases. The latest research shows that the drug sensitivity of CTC and metastasis is highly consistent, indicating that anti-tumor drug treatment for CTC can more effectively kill metastatic cancer cells, prolong the life of tumor patients, and improve the cure rate of tumors.


       In 2004, the US FDA approved CTC testing equipment for clinical testing

       In 2007, the American Society of Clinical Oncology (ASCO) included CTC as a tumor marker

       2013 CTC classification can accurately guide breast cancer medication

       2015 was rated as one of the top ten breakthrough technologies of the year


      The company's "Circulating Tumor Cell Extraction Kit" has recently submitted for registration inspection, and the Zhejiang Medical Device Inspection Institute is responsible for the effect inspection. This product is based on the negative immunomagnetic particle method and density gradient centrifugation method, by removing plasma, red blood cells, white blood cells and other components in the blood to achieve the enrichment of circulating tumor cells in the blood. It does not depend on the expression of tumor cell surface antigens, cell size, shape and other physical and chemical characteristics, the enrichment efficiency is high, and the enriched CTC maintains biological activity and has the widest applicability. This product will be the first CTC extraction reagent registered in China according to three types of medical devices.


Professional quality Trust brand
We are a high-tech enterprise specializing in the development and production of pharmaceuticals, biological products and testing reagents.
HANGZHOU GENESEA BIOTECHNOLOGY CO., LTD.
A high-tech enterprise specializing in the development and production of pharmaceuticals, biological products and testing reagents.
Address: 3rd Floor, Builiding 5, No. 1 Xiyuan Road, Xihu District, hangzhou, China
Email:info@genesbio.com
——————————————————————————————————————————————————————————————————————————————